Cost-effectiveness analyses (CEA) of SGLT2 inhibitors in heart failure consistently report favorable incremental cost-effectiveness ratios (ICERs) relative to commonly accepted willingness-to-pay thresholds in high-income countries. This evidence concerns the gene SLC5A2 and heart failure.